ES2096580T3 - Adn que codifica la proteina gp130 humana. - Google Patents

Adn que codifica la proteina gp130 humana.

Info

Publication number
ES2096580T3
ES2096580T3 ES90308530T ES90308530T ES2096580T3 ES 2096580 T3 ES2096580 T3 ES 2096580T3 ES 90308530 T ES90308530 T ES 90308530T ES 90308530 T ES90308530 T ES 90308530T ES 2096580 T3 ES2096580 T3 ES 2096580T3
Authority
ES
Spain
Prior art keywords
protein
dna coding
coding human
interleukin
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90308530T
Other languages
English (en)
Inventor
Tadamitsu Kishimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2096580T3 publication Critical patent/ES2096580T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PROTEINA GP130 HUMANA QUE TIENE AL MENOS LAS SIGUIENTES PROPIEDADES: (1) LA PROTEINA TIENE UNA AFINIDAD CON UN COMPLEJO DE IL-6 (INTERLEUQUIN-6) Y UN RECEPTOR IL-6 (RECEPTOR INTERLEUQUIN-6); (2) LA PROTEINA MUESTRA UN PESO MOLECULAR APARENTE DE 130 KDA EN LA ELECTROFORESIS POLIACRILAMIDA-SDS; Y (3) LA PROTEINA PARTICIPA EN LA TRANSMISION DE LA SEÑAL IL-6; EL CODIFICADOR DNA PARA LA PROTEINA, UNA EXPRESION PLASMIDA QUE CONTIENE EL DNA; Y UN PROCESO PARA LA PRODUCCION DE LA PROTEINA QUE USA LA EXPRESION PLASMIDA.
ES90308530T 1989-08-03 1990-08-02 Adn que codifica la proteina gp130 humana. Expired - Lifetime ES2096580T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20023089 1989-08-03
JP2140069A JP2898064B2 (ja) 1989-08-03 1990-05-31 ヒトｇｐ１３０蛋白質

Publications (1)

Publication Number Publication Date
ES2096580T3 true ES2096580T3 (es) 1997-03-16

Family

ID=26472699

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90308530T Expired - Lifetime ES2096580T3 (es) 1989-08-03 1990-08-02 Adn que codifica la proteina gp130 humana.

Country Status (10)

Country Link
US (1) US5132403A (es)
EP (1) EP0411946B1 (es)
JP (1) JP2898064B2 (es)
KR (1) KR0178384B1 (es)
AT (1) ATE147099T1 (es)
AU (1) AU635296B2 (es)
CA (1) CA2022610C (es)
DE (1) DE69029545T2 (es)
ES (1) ES2096580T3 (es)
IL (1) IL95235A (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ES2215359T3 (es) * 1991-12-18 2004-10-01 Icu Medical, Inc. Procedimiento de transferencia de fluido.
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
US5891998A (en) * 1993-06-23 1999-04-06 Istituto Di Ricerche Di Biologica Molecolare P. Angeletti S.P.A. Interleukin-6 receptor agonists
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
DE59503004D1 (de) * 1994-06-23 1998-09-03 Elin Ebg Motoren Gmbh Kühlung für einen motor
GB9419021D0 (en) 1994-09-21 1994-11-09 Applied Research Systems Therapeutic protein
AU700819B2 (en) 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
JP3458512B2 (ja) 1995-02-23 2003-10-20 東ソー株式会社 骨密度の変動推定方法又は骨そしょう症の診断方法及びこれに用いる試薬キット
KR19990022359A (ko) * 1995-06-07 1999-03-25 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 시토킨 시그날 트랜스듀서 ｇｐ130 ｍＲＮＡ에 특이적인 올리고뉴클레오티드
US5747470A (en) * 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US5674995A (en) * 1995-06-07 1997-10-07 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
EP0869176A4 (en) * 1995-11-07 2000-09-20 Kaneka Corp AUTOANTIGENS
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
WO2001016166A2 (en) * 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
EP1221482B1 (en) 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
GB0210539D0 (en) * 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
JP4837358B2 (ja) * 2005-10-19 2011-12-14 株式会社野村工電社 ボトル飲用水充填装置
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
ES2544888T3 (es) 2006-06-08 2015-09-04 Chugai Seiyaku Kabushiki Kaisha Prevención o remedio para enfermedades inflamatorias
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
US20080283557A1 (en) * 2007-05-17 2008-11-20 Julianne Desautels Spout for food stuff container
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
EP2226633A1 (en) * 2009-03-06 2010-09-08 Charité - Universitätsmedizin Berlin Uses and methods for the identification of a cytoprotective compound involving gp130 or LIFRalpha
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤
KR102351174B1 (ko) * 2020-05-11 2022-01-14 (주)아이테오솔루션즈 랜 포트의 혼동을 방지하는 어댑터 및 이를 포함하는 랜 포트 보안 장치
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha

Also Published As

Publication number Publication date
JP2898064B2 (ja) 1999-05-31
DE69029545T2 (de) 1997-07-24
AU635296B2 (en) 1993-03-18
EP0411946A3 (en) 1992-02-12
JPH0429997A (ja) 1992-01-31
KR0178384B1 (ko) 1999-04-01
IL95235A (en) 1995-11-27
KR910004801A (ko) 1991-03-29
US5132403A (en) 1992-07-21
AU6003990A (en) 1991-02-07
ATE147099T1 (de) 1997-01-15
DE69029545D1 (de) 1997-02-13
EP0411946B1 (en) 1997-01-02
CA2022610A1 (en) 1991-02-04
EP0411946A2 (en) 1991-02-06
IL95235A0 (en) 1991-06-10
CA2022610C (en) 2001-01-30

Similar Documents

Publication Publication Date Title
AU635296B2 (en) Human gp130 protein
AU639226B2 (en) Recombinant protein receptor
ES2136596T3 (es) Hil-6 modificada.
ATE358176T1 (de) Menschliche dnase
DE3789859D1 (de) Formen des Koloniestimulierungsfaktors 1.
DE3382837T2 (de) Herstellung von funktionellen, menschlichen Urokinaseproteinen
PT81691A (de) Hunde- und pferde-interferone
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
PT84915A (pt) Projectil porta-bombas com movimento helicoidal estabilizador
DE3870959D1 (de) 2-difluormethoxy-1,1,1,2-tetrafluoraethan als anaesthetikum.
IT8619370A0 (it) Molla elicoidale, nonche'procedimento per la sua fabbricazione.
DE3850654D1 (de) Immunglobulin-e-kompetitor.
FI875324A0 (fi) Hybridproteiner.
DE3575456D1 (de) Auflager.
DE3881406D1 (de) Cycloalkan(1,2-c:4,3-c')dipyrazole.
IT8822286A0 (it) Miscela di caucciu' reticolabile, in particolare vulcanizzabile mediante zolfo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 411946

Country of ref document: ES